Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Abbott AxSYM U.S. Presence May Give Firm Edge Over BNP Competitors

Related Content

Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection

Jun 17 2002

Biosite Triage BNP Reduces Diagnosis Uncertainty To 11%, NEJM Study Finds

Jul 22 2002

Roche NT-proBNP CHF Test Launch Expected By Jan. Pending FDA Approval

May 13 2002

More from Archive

More from Medtech Insight

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window